141 related articles for article (PubMed ID: 36306725)
1. Clinicopathological significance of major fusion oncogenes in papillary thyroid carcinoma: An individual patient data meta-analysis.
Vuong HG; Le HT; Le TTB; Le T; Hassell L; Kakudo K
Pathol Res Pract; 2022 Dec; 240():154180. PubMed ID: 36306725
[TBL] [Abstract][Full Text] [Related]
2.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
3. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
4. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children.
Cordioli MI; Moraes L; Bastos AU; Besson P; Alves MT; Delcelo R; Monte O; Longui C; Cury AN; Cerutti JM
Thyroid; 2017 Feb; 27(2):182-188. PubMed ID: 27849443
[TBL] [Abstract][Full Text] [Related]
5. A Detailed Histologic and Molecular Assessment of the Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma.
Chou A; Qiu MR; Crayton H; Wang B; Ahadi MS; Turchini J; Clarkson A; Sioson L; Sheen A; Singh N; Clifton-Bligh RJ; Robinson BG; Gild ML; Tsang V; Leong D; Sidhu SB; Sywak M; Delbridge L; Aniss A; Wright D; Graf N; Kumar A; Rathi V; Benitez-Aguirre P; Glover AR; Gill AJ
Mod Pathol; 2023 Dec; 36(12):100329. PubMed ID: 37716505
[TBL] [Abstract][Full Text] [Related]
6. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases.
Hang JF; Chen JY; Kuo PC; Lai HF; Lee TL; Tai SK; Kuo CS; Chen HS; Li WS; Li CF
Mod Pathol; 2023 Sep; 36(9):100242. PubMed ID: 37307878
[TBL] [Abstract][Full Text] [Related]
7. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
9. The changing characteristics and molecular profiles of papillary thyroid carcinoma over time: a systematic review.
Vuong HG; Altibi AM; Abdelhamid AH; Ngoc PU; Quan VD; Tantawi MY; Elfil M; Vu TL; Elgebaly A; Oishi N; Nakazawa T; Hirayama K; Katoh R; Huy NT; Kondo T
Oncotarget; 2017 Feb; 8(6):10637-10649. PubMed ID: 27793009
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic alterations in papillary thyroid cancers of young patients.
Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
[TBL] [Abstract][Full Text] [Related]
11. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
12. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
[TBL] [Abstract][Full Text] [Related]
13.
Bastos AU; de Jesus AC; Cerutti JM
Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis using next generation sequencing in pediatric thyroid cancer reveals BRAF and fusion oncogenes are common.
Newfield RS; Jiang W; Sugganth DX; Hantash FM; Lee E; Newbury RO
Int J Pediatr Otorhinolaryngol; 2022 Jun; 157():111121. PubMed ID: 35397361
[TBL] [Abstract][Full Text] [Related]
15. Nodal Metastases Associated With Fusion Oncogenes Are Age Dependent in Young Adult Patients With Thyroid Cancer.
Li H; Han R; Meng L; Sun Y; Zhao M; Zhou W; Xie J; Yu D; Shen L; Zhou Y; Wang S; Yan J; Wang W; Ye L
J Clin Endocrinol Metab; 2023 Dec; 109(1):143-150. PubMed ID: 37536280
[TBL] [Abstract][Full Text] [Related]
16. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
[TBL] [Abstract][Full Text] [Related]
17. Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.
Lee MY; Ku BM; Kim HS; Lee JY; Lim SH; Sun JM; Lee SH; Park K; Oh YL; Hong M; Jeong HS; Son YI; Baek CH; Ahn MJ
Cancer Res Treat; 2017 Oct; 49(4):906-914. PubMed ID: 28052655
[TBL] [Abstract][Full Text] [Related]
18. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
19. Molecular and Cytogenetic Features of NTRK Fusions Enriched in BRAF and RET Double-Negative Papillary Thyroid Cancer.
Wu S; Liu Y; Li K; Liang Z; Zeng X
J Mol Diagn; 2023 Aug; 25(8):569-582. PubMed ID: 37236546
[TBL] [Abstract][Full Text] [Related]
20. Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation.
Musholt TJ; Schönefeld S; Schwarz CH; Watzka FM; Musholt PB; Fottner C; Weber MM; Springer E; Schad A
Langenbecks Arch Surg; 2010 Sep; 395(7):877-83. PubMed ID: 20640859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
